TScan Therapeutics (TCRX) Current Leases (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Current Leases of $7.4 million for Q1 2026, up 49.63% year-over-year from $5.0 million in Q1 2025, and up 3.78% quarter-over-quarter from $7.2 million in Q4 2025.
TScan Therapeutics (TCRX) Current Leases (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Current Leases for 7 consecutive years, with $7.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 49.63% year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $7.4 million (up 49.63% YoY), while the FY2025 annual figure was $7.2 million, up 56.83% from the prior year.
- Current Leases advanced to $7.4 million in Q1 2026 per TCRX's latest filing, from $7.2 million in the prior quarter.
- Across five years, Current Leases topped out at $7.4 million in Q1 2026 and bottomed at $1.7 million in Q1 2022.
- Historically, Current Leases has averaged $4.3 million across 5 years, with a median of $3.9 million in 2024.
- Annual changes were most pronounced in 2023 — Current Leases soared 143.79% — and 2024, when it decreased 14.14%.
- TScan Therapeutics' Current Leases stood at $3.7 million in 2022, then dropped by 11.82% to $3.2 million in 2023, then soared by 40.79% to $4.6 million in 2024, then soared by 56.83% to $7.2 million in 2025, then grew by 3.78% to $7.4 million in 2026.
- Business Quant data shows TCRX's Current Leases at $7.4 million in Q1 2026, $7.2 million in Q4 2025, and $6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 7.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.72 Mn |
| Mar 31, 2026 | 7.44 Mn |
| Dec 31, 2025 | 7.17 Mn |
| Sep 30, 2025 | 6.90 Mn |
| Jun 30, 2025 | 6.29 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Dec 31, 2024 | 4.57 Mn |
| Sep 30, 2024 | 3.90 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Mar 31, 2024 | 3.34 Mn |
| Dec 31, 2023 | 3.25 Mn |
| Sep 30, 2023 | 4.38 Mn |
| Jun 30, 2023 | 4.21 Mn |
| Mar 31, 2023 | 3.84 Mn |
| Dec 31, 2022 | 3.68 Mn |
| Sep 30, 2022 | 1.80 Mn |
| Jun 30, 2022 | 1.75 Mn |
| Mar 31, 2022 | 1.70 Mn |
| Dec 31, 2021 | 1.65 Mn |
| Sep 30, 2021 | 1.62 Mn |